(Note: IPOScoop has “No Call” on this offering. This is not an IPO. This is a unit offering and a NASDAQ uplisting from the U.S. OTCQB marketplace, where BriaCell Therapeutics Corp.’s common stock trades under the symbol “BCTXF.” The stock also trades on the TSX Venture Exchange or TSXV under the symbol “BCT” and on the Frankfurt Stock Exchange under the symbol “8BTA.”)

BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer, with a focus on advanced breast cancer. BriaCell has completed positive proof-of-concept studies of Bria-IMT™, a whole cell targeted immunotherapy, in patients with advanced breast cancer. BriaCell has been conducting a Phase I/IIa clinical trial of Bria-IMT™, BriaCell’s lead candidate, in a Combination Study with immune checkpoint inhibitors and has initiated combination therapy with the Incyte drugs INCMGA00012 (an anti-PD-1 antibody) and epacadostat, an orally bioavailable small-molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1). BriaCell and Incyte Corporation have formed a non-exclusive clinical trial collaboration to evaluate the effects of combinations of novel clinical candidates. BriaCell is also developing Bria-OTS™, an off-the-shelf personalized immunotherapy, for advanced breast cancer.

(Note: BriaCell Therapeutics priced its NASDAQ uplift offering on Feb. 23, 2021: 5.88 million units at $4.25 each to raise $24.99 million. The terms in the prospectus called for the offering of up to 3.27 million (3,268,765) common units, each consisting of a common share and a warrant to purchase one common share, and/or up to 3.27 million (3,268,765) pre-funded units, each consisting of a pre-funded warrant to purchase one common share and a warrant to purchase one common share. **Note: The common stock and the warrants are expected to start trading on Feb. 24, 2021, on the NASDAQ with the stock trading under the symbol “BCTX” and the warrants under the symbol “BCTXW.”)